BioNTech (BNTX) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Qiagen N.V. (QGEN) has outperformed BioNTech (BNTX) over the past year, gaining 5.3% versus a loss of 15.3%. Over five years, QGEN leads with a -15.4% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $10.18 billion), about 2.0 times the size.
Qiagen N.V. pays a dividend yielding 0.71%, while BioNTech does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | QGEN |
|---|---|---|
| Share price | $80.96 | $49.30 |
| Market cap | $20.07B | $10.18B |
| 1-day change | -0.52% | -0.66% |
| YTD return | -14.96% | +9.63% |
| 1-year return | -15.30% | +5.25% |
| 5-year return | -76.74% | -15.40% |
| P/E ratio (TTM) | — | 26.65 |
| Forward P/E | — | 18.48 |
| EPS (TTM) | $-6.83 | $1.85 |
| Dividend yield | 0.00% | 0.71% |
| Annual dividend | $0.00 | $0.35 |
| Revenue (latest FY) | — | $2.09B |
| Revenue growth (YoY) | — | +5.65% |
| Net income (latest FY) | — | $424.88M |
| Gross margin | — | 62.18% |
| Operating margin | — | 22.29% |
| Net margin | — | 20.33% |
| 52-week high | $124.00 | $57.82 |
| 52-week low | $79.52 | $32.53 |
| Distance from 52-week high | -34.71% | -14.74% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +38.51% | +0.95% |
| Average volume | 1.08M | 3.65M |
| Shares outstanding | 247.93M | 206.50M |
| Employees | 7,807 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QGEN has outperformed BNTX by 20.6 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,400 employees
BNTX vs QGEN FAQ
Which is bigger, BioNTech or Qiagen N.V.?
BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $10.18B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, BNTX or QGEN?
QGEN returned +5.25% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BioNTech or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.71%, while BioNTech does not currently pay a regular dividend.
Are BioNTech and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.